In May, Biogen (Nasdaq:BIIB) CEO Michel Vounatsos announced his resignation following a precipitous decline in its share price after failing to achieve material sales of its Alzheimer’s drug Aduhelm (aducanumab). Roughly half a year later, Biogen has installed the German-Canadian executive Christopher Viehbacher to lead the company.
Viehbacher will assume the role of president, CEO and board member starting on November 14.
The new CEO has a diverse background. In 2015, he co-founded the Cambridge, Massachusetts–based investment firm Gurnet Point Capital. The investment firm has supported Radius Health and the oncology company Naveris.
Viehbacher is also a board member of Crossover Health and Before Brands, and is the board chair at Vedanta Biosciences and PureTech Health.
Christopher A. Viehbacher
He was the CEO of Sanofi (Nasdaq:SNY) from 2008 to 2014. In that time frame, the company’s …